| Title: |
635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study |
| Authors: |
Van den Eynde, Marc; Huyghe, Nicolas; Sinapi, Isabelle; De Cuyper, Astrid; Verstraelen, Eleonore; Goffette, Pierre; Ghaye, Benoît; Papier, Matthias; Bedognetti, Davide; van Maanen, Aline; Castella, Marie-Laure; Galon, Jerôme; Carrasco, Javier; ESMO Congress 2023 |
| Contributors: |
UCL - SSS/IONS/NEUR - Clinical Neuroscience; UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale; UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie; UCL - (SLuc) Clinical Trial Center; UCL - (SLuc) Service de radiologie; UCL - (SLuc) Service d'oncologie médicale; UCL - (SLuc) Centre du cancer |
| Source: |
Annals of Oncology, Vol. 34, no.Suppl 1, p. S450 (2023) |
| Publisher Information: |
Elsevier |
| Publication Year: |
2023 |
| Collection: |
DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| Subject Terms: |
Oncology; Hematology |
| Description: |
BACKGROUND : Cetuximab could mediate, independently from RAS mutation, an immunogenic tumor cell death and antitumor immune response. This trial explores the efficacy and safety of AVE, CET and IRI for the treatment of refractory MSS mCRC. [.] |
| Document Type: |
conference object |
| Language: |
English |
| Relation: |
boreal:285089; http://hdl.handle.net/2078.1/285089 |
| DOI: |
10.1016/j.annonc.2023.09.1825 |
| Availability: |
http://hdl.handle.net/2078.1/285089; https://doi.org/10.1016/j.annonc.2023.09.1825 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.F997E341 |
| Database: |
BASE |